At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02268 WUXI XDC
Not Yet Opened 04-22 16:08:30
59.350
-0.400
-0.67%
High60.400Low58.500Vol2.89M
Open59.400D1 Closing59.750Amplitude3.18%
Mkt Cap74.78BTradable Cap74.78BTotal Shares1.26B
T/O171.50MT/O Rate0.23%Tradable Shares1.26B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
CMB International Reports Moderate Recovery in Healthcare Sector Risk Appetite, Recommends Six Stocks Including Hansoh Pharma
Stock News  ·  04-20 13:50
CMB International Reports Moderate Recovery in Healthcare Sector Risk Appetite, Recommends Six Stocks Including Hansoh Pharma
Assessing WuXi XDC Cayman (SEHK:2268) Valuation After New Akari Therapeutics ADC Partnership
Simply Wall St.  ·  04-10
Assessing WuXi XDC Cayman (SEHK:2268) Valuation After New Akari Therapeutics ADC Partnership
Akari CEO says WuXi XDC partnership accelerates AKTX-101 IND toward late 2026
Reuters  ·  04-09
Akari CEO says WuXi XDC partnership accelerates AKTX-101 IND toward late 2026
WUXI XDC Issues 1.203 Million Shares Following Option Exercise
Stock News  ·  04-08
WUXI XDC Issues 1.203 Million Shares Following Option Exercise
WuXi XDC approves 4.85 million restricted shares for 425 staff under 2024 scheme
Bulletin Express  ·  04-08
WuXi XDC approves 4.85 million restricted shares for 425 staff under 2024 scheme
WuXi XDC files HKEX next-day return, issues 1,507,353 shares at HKD 1.8-7.5
Reuters  ·  04-08
WuXi XDC files HKEX next-day return, issues 1,507,353 shares at HKD 1.8-7.5
WuXi XDC grants 4,854,500 nil-cost restricted shares under 2024 scheme
Reuters  ·  04-08
WuXi XDC grants 4,854,500 nil-cost restricted shares under 2024 scheme
WuXi XDC Adds 0.84 Million Shares in March 2026 as Pre-IPO Options Are Exercised
Bulletin Express  ·  04-08
WuXi XDC Adds 0.84 Million Shares in March 2026 as Pre-IPO Options Are Exercised
Akari partners with WuXi XDC to accelerate PH1 ADC payload development, IND by 2026
Reuters  ·  04-06
Akari partners with WuXi XDC to accelerate PH1 ADC payload development, IND by 2026
HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio Up 7%; Hengrui Pharma And Junshi Bio Up 6%; HBM, Beigene, Sihuan Pharm Up 5%
Tiger Newspress  ·  03-27
HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio Up 7%; Hengrui Pharma And Junshi Bio Up 6%; HBM, Beigene, Sihuan Pharm Up 5%
HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.
Tiger Newspress  ·  03-26
HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.
CLSA Raises Target Price for WUXI XDC to HK$80.9, Citing Improved Profit Visibility
Stock News  ·  03-25
CLSA Raises Target Price for WUXI XDC to HK$80.9, Citing Improved Profit Visibility
CICC Maintains Outperform Rating on WUXI XDC with HK$88.0 Target Price
Stock News  ·  03-25
CICC Maintains Outperform Rating on WUXI XDC with HK$88.0 Target Price
WuXi XDC Cayman (SEHK:2268) Margin Slip Tests Bullish Growth Narrative After FY 2025 Earnings
Simply Wall St.  ·  03-24
WuXi XDC Cayman (SEHK:2268) Margin Slip Tests Bullish Growth Narrative After FY 2025 Earnings
Morgan Stanley Assigns "Overweight" Rating to WUXI XDC (02268) with HK$86 Price Target
Stock News  ·  03-24
Morgan Stanley Assigns "Overweight" Rating to WUXI XDC (02268) with HK$86 Price Target
From Enabler to Innovator: WUXI XDC's Evolution and Value Transformation in the CRDMO Sector
Stock News  ·  03-24
From Enabler to Innovator: WUXI XDC's Evolution and Value Transformation in the CRDMO Sector
Pharmaceutical Sector Leads Hong Kong Market Rebound with Strong ETF Performance
Deep News  ·  03-24
Pharmaceutical Sector Leads Hong Kong Market Rebound with Strong ETF Performance
HK Pharma Stocks Gained. Wuxi XDC Up 8%; Wuxi AppTec Up 7%; Transthera And HBM Up 5%; Keymed Bio And Innocare Up 4%; Wuxi Bio And Remegen Up 3%
Tiger Newspress  ·  03-24
HK Pharma Stocks Gained. Wuxi XDC Up 8%; Wuxi AppTec Up 7%; Transthera And HBM Up 5%; Keymed Bio And Innocare Up 4%; Wuxi Bio And Remegen Up 3%
Stock Track | WUXI XDC Soars 5.22% Intraday on Strong Fiscal Year Results
Stock Track  ·  03-24
Stock Track | WUXI XDC Soars 5.22% Intraday on Strong Fiscal Year Results
BRIEF-Wuxi Xdc Cayman Inc Posts FY Adjusted Net Profit Attributable RMB1.56 Billion
Reuters  ·  03-23
BRIEF-Wuxi Xdc Cayman Inc Posts FY Adjusted Net Profit Attributable RMB1.56 Billion

Introduction

Company Name.
WUXI XDC
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
WuXi XDC Cayman Inc is an investment holding company principally engaged in the provision of comprehensive contract research, development and manufacturing organization (CRDMO) services for antibody drug conjugate (ADC) and other bioconjugates. The Company's services include the discovery, process development and Good Manufacturing Practice (GMP) manufacturing for bioconjugates, monoclonal antibody intermediates and payload-linkers associated with bioconjugates. The Company provides CRDMO services to customers through contracts under fee-for-service (FFS) basis and contracts under full-time equivalent (FTE) basis. The Company principally conducts its businesses in domestic and overseas markets, including North America, Europe and the rest of the world.
Issue price:
--